natgillin/translations-raw huggingface dataset:
Column: 30 X 4.6 mm Waters Symmetry C18 column with 3.5 µm particle size; solventsystem: A = water/trifluoroacetic acid (100:0.05) and B = water/acetonitrile/trifluoroacetic acid (5:95:0.03); method: Linear gradient elution with 90% A to 100% B in 4 min and with a flow rate of 2 ml/min. or (method B): on a Micromass LCT instrument equipped with a 4-way MUX ElectroSpray source, a Micromass Waters MUX-2488 UV-detector, a Sedex 754 4-channels LT-ELS-detector, a CTC Analytics HTS-PAL autosampler equipped with 4 injection valves, and 4 Waters 1525 Binary HPLC pumps. 
Kolona: 30 x 4,6 mm vodene simetrije C18 kolona s 3.5 um veličinom čestica; sistem otapala: A = vodaftrifluorooctena kiselina (100:0.05) i B = voda/acetonitril/trifluorooctena kiselina (5:95:0.03); postupak: linearni gradijent ispiranja s 90% A do 100% B u 4 min i sa ratom protoka od 2 ml/min ili (metoda B): na mikromasenom LCT instrumentu opremljenom s 4-načinskim MIX ElectroSpray izvorom, mikromasenim vodenim MUX-2488 UC-detektorom, Sedex 754 s 4-kanalnim LT-ELS detektorm, CTC analitičkim HTS-PAL autosemplerom koji je opremljen s 4 injekciona zaliska, i 4 vodene 1525 binarne HPLC pumpe.
Efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack and by reduced requirement for other, symptomatic therapy, e.g., anti-inflammatory, e.g., corticosteroid; or bronchodilator, e.g., B2 adrenergic, therapy. 
Učinkovitost u liječenju astme vidjet će se po smanjenoj učestalosti ili ozbiljnosti simptomatičnog napada, npr. akutnog astmatičnog ili bronhokonstrikcijskog napada 1 po smanjenoj potrebi za drugom, simptomatičnom terapijom, npr. antiupalnom, npr. kortikosteroidnom; ili bronhodilatorskom, npr. B2 adrenergnom terapijom.
Moreover, in this aspect, the invention relates to proteins or peptides which comprise an amino acid sequence selected from the group consisting of the sequences according to SEQ ID NOs: 10 and 12-14 of the sequence listing. 
Uporaba protutijela u metodi za detekciju tumorskih stanica koje eksprimiraju antigen povezan s tumorom, pri čemu se protutijelo veže na antigen povezan s tumorom, pri čemu se protutijelo može dobiti imunizacijom s peptidom ili polipeptidom koji ima sekvencu aminokiselina odabran iz skupine koja se sastoji od SEQ ID NO:
Medicament or pharmaceutical composition according to any one of claims 8 to 11, wherein said subject does not respond adequately to, or is unlikely to respond adequately to, one or more therapeutic agents in the group of corticoids, anti-TNF, anti-interleukins, anti-B lymphocytes, anti-costimulatory molecules, tolerogenic agents, anti-complement proteins, inhibitors of T cell signaling molecules, inhibitors of cell migration, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, azathioprine, cyclosporine, minocycline, D-penicillamine. 
Smjesa, lijek ili farmaceutski pripravak za upotrebu prema bilo kojem zahtjevu od 1 do 8, naznačeni time da potrebiti pacijenti ne reagiraju adekvatno ili je mala vjerojatnost da će reagirati adekvatno na davanje jednog ili više terapijskih sredstava (agensa) iz skupine kortikoida, anti-TNF lijekova, anti-interleukina, protutijela za B-limfocite, anti-kostimulirajućih molekula, tolerogenih agensa, protutijela za proteine komplement sustava, inhibitora signalnih molekula za T-limfocite, inhibitora migracija stanica, metrotreksata, leflunomida, sulfasalazina, hidroksiklorokina, azatriopina, ciklosporina, minociklina i D-penicilamina.
The organic phase was washed with brine, dried with MgSO4 and concentrated in vacuo to give 0.112 g 2-(5-fluoro-1H-indol-3-ylsulfanyl)-benzylamine (98%). 
Organska faza se pere u rasolu i suši s MgSO, te koncentrira in vacuo kako bi se dobilo 0.112 g 2-(5-fluoro-1H-indol-3-ilsulfanil)-benzilamina (98%).
A composition comprising at least one isolated IL-6 antibody according to any of claims 1-5 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Sastav koji sadrži najmanje jedno izolirano IL-6 antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 4 i najmanje jedan farmaceutski prihvatljiv nosač ili razrjeđivač. Preparat prema patentnom zahtjevu 10 koji nadalje sadrži najmanje jedan spoj ili polipeptid izabran iz grupe koju čine detektabilna oznaka ili reporter, antagonist TNF, anti-infektivni lijek, lijek za kardiovaskularni (KV) sustav, lijek za središnji živčani sustav (CNS), lijek za autonomni živčani sustav (ANS), lijek za respiratorni trakt, lijek za gastrointestinalni (GI) trakt, hormonski lijek, lijek za održavanje ravnoteže fluida ili elektrolita, hematološki lijek, antineoplastik, imunomodulatorni lijek, oftamološki, otički ili nazalni lijek, topički lijek, nutriticionistički lijek, citokin ili antagonist citokina.
On completion of addition stirring was continued for 1.5 h then the reaction was quenched with saturated aqueous ammonium chloride solution (80 mL). 
HR P20080668 T3 je dodavanje gotovo, s miješanjem se nastavi još 1,5 sati, te se reakcijsku smjesu ugasi zasićenom vodenom otopinom amonijevog klorida (80 ml).
The monoclonal antibody of claim 8, wherein the monoclonal antibody is coupled to a detectable marker selected from a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound. 
Protutijelo ili fragment prema zahtjevu 6, naznačen(0) time, da je protutijelo ili fragment spojen/o na marker koji se može otkriti, pri čemu je taj marker radioizotop, metalni kelator, enzim, fluorescentni spoj, bio-iluminacijski spoj ili kemijsko-iluminacijski spoj.
The anti-TNFa antibody, for use according to claim 14, wherein the subject is intolerant to oral antibiotics, has a contraindication to oral antibiotics, or has an inadequate response to oral antibiotics. 
Anti-TNFa protutijelo za uporabu prema zahtjevu 14, naznačeno time, da je subjekt netolerantan na oralne antibiotike, ima kontraindikaciju za oralne antibiotike, ili ima neadekvatan odgovor na oralne antibiotike.
determining a frequency offset between the said universal frequency reference signal received from the central station (M) and the said local frequency reference signal; characterised in that it includes the operations of: 
- < određivanje odlazne frekvencije između spomenutog referentnog signala univerzalne frekvencije zaprimljenog iz centralne stanice (M) i spomenutog referentnog signala lokalne frekvencije; naznačen time, da uključuje radnje:
and the pharmacologically acceptable salts thereof. 
A ili njegove farmakološki prihvatljive kiselinske adicijske soli.
A host cell transformed with a vector of claim 5, wherein optionally the host cell is derived from the group consisting of Saccharomyces, Schizosaccharomyces, Kluyveromyces, Pichia, Pichia, Hansenula, Aspergillus, Trichoderma, Penicillium, Chrysosporium, Chaetomium, Acremonium, Candida and Yarrowina, and/or 
Stanica domaćina naznačena time da je transformirana vektorom iz patentnog zahtjeva 5, gdje je po mogućnosti (i) stanica domaćina dobivena iz skupine koja se sastoji od pivskog kvasca, kvasca Schizosaccharomyces, kvasca Kluyveromyces, kvasca Pichia, kvasca Pichia, kvasca Hansenula, gljivica Aspergillus, gljivica Trichoderma, Kistaca, gljiva Chrysosporium, plijesni Chaetomium, plijesni Acremonium i kvasnice Candida i Yarrowina, i/ili
said second ISV has high affinity for/binds to a first antigen on a target cell; wherein said first antigen is different from said TCR; and wherein said target cell is different from said T cell, and wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: 
navedeni drugi ISV ima visoki afinitet za/vezanje na prvi antigen na ciljanoj stanici; pri čemu je navedeni prvi antigen različit od navedene TCR; i pri čemu se navedena ciljna stanica razlikuje od navedene T stanice, i pri čemu se navedeni prvi ISV u osnovi sastoji od 4 okvirne regije (FR1 do FR4, redom) i 3 regije koje određuju komplementarnost (CDRI do CDR3, redom), u kojima:
is a group represented by wherein W2 represents a hydrogen atom, C1-C6 alkyl group or halogen atom (with the proviso that, occurrence of W2 on a benzene ring may be 1 to 3, and may be the same or different); n1 represents 1 to 5; n2 represents 1 to 4; and n3 represents 1 to 6, 
an gdje W2 predstavlja vodikov atom, Ck alkilnu skupinu ili atom halogena (pod uvjetom da kada je to W2 na benzenovom prstenu može biti 1 do 3, te može biti isti ili različit); nl predstavlja 1 do 5; n2 predstavlja 1 do 4; a n3 predstavlja 1 do 6, rečena skupina po izboru ima 1 do 4 skupine odabrane iz skupine Al koja se sastoji od atoma 15
On cooling the vial was opened and the contents filtered through a Whatman 5 µM filter tube, washing the filter cake with methanol (2x1 mL). 
Nakon hlađenja bočicu se otvori, a sadržaj pročisti kroz 5 uM cijevni Whatmanov filtar, uz ispiranje filtarskog kolača metanolom (2 X 1 ml).
wherein R1 is difluoromethyl or trifluoromethyl; Y is —CHR2— or and R2 is hydrogen or C1-C6alkyl; or a tautomer of such a compound; and component B) is a compound selected from compounds known for their fungicidal and/or insecticidal activity, is particularly effective in controlling or preventing fungal diseases of useful plants. 
MOO (D, pri čemu R, je difluorometil ili trifluorometil; Y je ili pe ==ZCH, a Ro je vodik ili C,-Csalkil; ili tautomer takvog spoja; te komponenta B) je spoj koji je odabran iz skupine koja sadrži Azoksistrobin; Pikoksistrobin; Ciprokonazol;
precipitating IgG from the first supernatant, in a second precipitation step, with between about 20% and about 25% alcohol at a pH of between about 6.7 and about 7.3 to form a second precipitate; 
taloženje IgG iz sloja s površine s oko 20% do oko 30% alkohola na nižoj temperaturi i na pH-vrijednosti od oko 6,7 do oko 7,3, za tvorbu prvog taloga,
The product was purified by reverse phase semi-prep scale HPLC to yield 50mg of 7-O-methylthiomethyl-9-a-OH-10- epi paclitaxel of Formula 20 as a white solid. 
Proizvod je bio očišćen pomoću reverzne faze polu-preparativne skale na stupcu HPLC, da bi se dobilo 50 mg 7-O-metiltiometil-9-a-OH-10-epi paklitaksela formule 20, kao bijele krutine.
A process for preparing compound of formula (IV) polymorphic Form B: said process comprising: 
Postupak pripreme spoja formule (IV) polimorfnog oblika B:
a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu so!
grinding and/or dispersing and/or upconcentrating the at least one mineral matter of step (a) in the presence of from 0.05 wt % to 1 wt %, relative to the total dry mineral material, of the at least one partially or totally lithium-neutralized water-soluble organic polyacrylic acid of step (b) in water to obtain an aqueous mineral material comprising calcium carbonate and the at least one partially or totally lithium-neutralized water-soluble polyacrylic acid, 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, karakteriziran na način da je barem jedan djelomično ili potpuno litijem neutraliziran u vodi topljiv organski polimer prisutan u količini od 0.001 wt% do 5 wt%, poželjno od 0.01 wt% do 2 wt%, najpoželjnije od 0.05 wt% do 1 wt%, u odnosu na ukupni suhi mineralni materijal.
In accordance with a second aspect of the invention, there is provided a pharmaceutical composition comprising a compound according to the first aspect of the invention, together with one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, uz jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
Compact fluorescent lamp according to claim 2, characterized in that the insertion (10) is adapted for transmission of an optical or radio-frequency signal waves. 
Kompaktna fluorescentna žarulja prema zahtjevu 2, naznačena time što je umetak (10) prilagođen za prijenos valova optičkog ili radio signala.
Modified bases comprise synthetic and natural bases such as inosine, xanthine, hypoxanthine and other -aza, deaza, -hydroxy, -halo, -thio, thiol, -alkyl,-alkenyl, -alkynyl, thioalkyl derivatives of pyrimidine and purine bases that are or will be known in the art. 
7. < Oligonukleotid u skladu s patentnim zahtjevom 6, naznačen time što je modificirana baza sintetska ili prirodna baza, poput inozina, ksantina, hipoksantina i drugih -aza, -deaza, -hidroksi, -halogeniranih, -tio, -tiolnih, -alkilnih, - alkenilnih, -alkinil, -tioalkilnih derivata pirimidinskih i purinskih baza.
The combination for use according to claim 7, wherein the insulin secretagogue is glipizide. 
Kombinacija za uporabu prema zahtjevu 3, naznačena time da je metformin prisutan u obliku metformin hidroklorida.
The process of claim 7, characterized in that new, whole polystyrene foam balls with a diameter of 1-15 mm, or crushed or granulated polystyrene foam, or waste polystyrene foam, or perlite or chopped wood is used as lightening material. 
Postupak prema zahtjevu 11, naznačen time što se kao olakšavajući materijal koriste nove, cijele kuglice od polistirenske pjene promjera 1-15 mm, ili zdrobljena ili granulirana polisterinska pjena, ili otpadna polistirenska pjena, ili perlit ili sjeckano drvo.
the polypeptides i) and ii) of the conjugate are covalently linked in a fusion protein; and 
polipeptidi i) i ii) konjugati kovalentno vezani u fuzijskom proteinu; i
The system according to claim 9, wherein the weighted average is calculated using an equation EPMATHMARKEREP wherein wi indicates incremental weightage, MRi indicates RSRP values received for the plurality of neighbor cells, k indicates the periodic intervals of time of receiving the RSRP values and RSRPn is the weighted average of the RSRP values. 
. . . . RSRP,, = či gdje w; označuje ponderiranje inkrementa, MR; označuje RSRP vrijednosti primljene za više i=o Wi susjednih ćelija, k označuje periodne intervale vremena primanja RSRP vrijednosti, a RSRP,, je ponderirani prosjek RSRP vrijednosti.
The method of claim 51, wherein the neuromuscular disorder is a disorder of the motor unit chosen from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth disease, and Guillain-Barre Syndrome. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 18, ili njegova farmaceutski prihvatljiva sol, za upotrebu u postupku liječenja bolesti odabrane od Amiotrofne Lateralne Skleroze (ALS), Spinalne Mišićne Atrofije (SMA) i miastenije gravis.
Use of a compound according to claim 1 or a pharmaceutical composition according to claim 2 in the manufacture of a medicament for treating a disease and/or disorder of the eye. 
Uporaba spoja ili farmaceutskog pripravka prema zahtjevu naznačena time da je za proizvodnju medikamenta za liječenje i/ili poremećaja oka.
The device of claim 1, wherein at least one of the first clamp and the second clamp has at least one non-adjustable lug. 
Uređaj sukladno patentnom zahtjevu 1 ili 2, naznačen time što, najmanje jedna od stezaljki (1, 2) koje su stegnute na dnu tračnice ima najmanje jedan nepodesivi jezičac (12).
A method of treating IBD, the method comprising administering to a subject in need thereof a therapeutically effective amount of an IL-22 Fc fusion protein comprising the amino acid sequence of SEQ ID NO:8. 
Izolirana nukleinska kiselina prema zahtjevu 11, naznačena time, da nukleinska kiselina koja kodira fuzijski protein Fc IL-22, obuhvaća ili se sastoji od aminokiselinske sekvence od SEQ ID NO:8 ili SEQ ID NO:10.
The apparatus of clause 1, wherein the height of the downstream portion inhibits passage therethrough of a circulating tumor cell. 
Uređaj prema patentnom zahtjevu 1, pri čemu visina donjeg dijela sprečava prolaz cirkulirajućim stanicama tumora i olakšava prolaz crvenim krvnim zrncima čovjeka.
a cushioning support (10) adapted to be anchored to the floor of the stable to support the weight of a livestock; 
Prostirka koji se sastoji od - podstave (10) dizajnirane tako da se može pričvrstiti za pod štale 1 izdržati težinu stoke -
Ra and Rb are selected from H, halogen, C1 to C6 alkyl; or Ra and Rb, together with the carbon atom to which they are attached, form a 3-, 4-, 5- or 6-membered ring, optionally containing one or two heteroatoms selected from O, N and S; M is H, C1-3 alkyl or a pharmaceutically acceptable cation; is N, CH, C(halogen) or C(C1-C4 alkyl); 
R*i R' su odabrani iz H, halogena, C; do C, alkil; ili R*i R", zajedno s atomom ugljika za koji su povezani, tvore 3-, 4-, 5- ili 6-člani prsten, koji izborno sadrži jedan ili dva heteroatoma odabrana iz O, N 1 S; M je H, C,3 alkil ili farmaceutski prihvatljiv kation; x jeN, CH, C(halogen) ili C(C;-Ca alkil);
A combination of any one of claims 1 to 6 for use in the treatment or prevention of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage. 
Kombinacija prema bilo kojem od patentnih zahtjeva 1-10 za uporabu u liječenju ili prevenciji karcinoma, upalnih bolesti, reperfuzijskih povreda, ishemijskih stanja, moždanog udara, bubrežne insuficijencije, kardiovaskularnih bolesti, vaskularnih bolesti različitih od kardiovaskularnih bolesti, dijabetesa, neurodegenerativnih bolesti, retrovirusnih infekcija, oštećenja retine ili starenja kože i oštećenja kože izazvanih UV-zračenjem.
wherein R1 is as defined for the compound of formula (IIb), with a chiral amine of formula (Vb) 
(lb) pri čemu su R1, R2 1 R6 kao što su definirani u zahtjevu 3; 1 kiralni amin formule (V) ima formulu (Vb):
A method for preparing a compound of Formula II, or racemate, or pharmaceutically acceptable salt thereof, comprising the steps of: 
Postupak pripreme spoja Formule II, ili njegovog racemata ili farmaceutski prikladne soli, koji obuhvaća korake:
The prodrug of any of claims 8 to 13, wherein the backbone moieties are linked together through crosslinker moieties comprising the following structure wherein q is an integer from 3 to 100. 
Predlijek prema bilo kojem od zahtjeva 6 do 11, naznačen time što su dijelovi okosnice međusobno povezani preko dijelova umreživača koji sadrže sljedeću strukturu pri čemu q je cijeli broj od 3 do 100.
The antibody or a functional fragment of the antibody according to claim 1 or 2 which inhibits the process of cell fusion of osteoclasts. 
Monoklonsko antitijelo ili njegov funkcionalni fragment, sukladno sa zahtjevom 1 ili 2, koji inhibiraju proces fuzije stanica osteoklasta.
The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R5 is hydrogen and if R4 is methyl or Cl then R7 cannot be methyl or Cl. 
Spoj prema patentnom zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, gdje R3 je izabran od vodika, metila, F ili Cl; i R5 je vodik.
the valine at position 2 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, F, I, L, M, Q, T, W, or Y; 
(i) valin na položaju 2 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine kojučne A, C,F,1,L,M,Q,T, W te Y;
Binding of the antibodies was detected using an anti-human IgG-HRP conjugate (Sigma, #A7340X). 
Vezanje protutijela detektirano je uz pomoč konjugata protuljudski lgG-HRP (Sigma. br.
A composition for use in improving a social domain in a human having autism, wherein the composition includes a therapeutically effective amount of at least one gamma-aminobutyric acid agonist. 
Pripravak namijenjen upotrebi u poboljšavanju socijalnih vještina kod osobe s autizmom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista Y-aminomaslačne kiseline.
n is an integer from 1 to 8; 
n je je cijeli broj od 1 do 8;
A compound of formula II: wherein 
Spoj sa formulom II: [image] naznačen time da
The compound according to claim 1, which is 3-(5-fluoropyrimidin-4-yl)-3-methyl-6-(1H-pyrazol-4-yl)isoindolin-1-one, isomer 1, or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je S enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6- (1H-pirazol-4-il)izoindolin-1-ona, ili njegova farmaceutski prihvatljiva sol.
The panel according to claim 12, wherein the photovoltaic cells are formed directly on the upper plateau by vacuum deposition methods. 
Ploča prema zahtjevu 18, naznačena time što se fotonaponske ćelije proizvode izravno na gornjoj plohi (7, 7) postupcima vakuumskog taloženja.
Package according to anyone of claims 1 to 29, characterised in that the package (1; 80; 90; 100) contains tobacco-related articles, wherein the tobacco-related articles are selected from the following group: cigarettes, cigarillos, cigars, tobacco-containing rods, smokeless tobacco, simulated smoking devices, inhalors without combustion of tobacco, aroma reservoirs. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 29, naznačen time što omot za pakiranje (1; 80; 90; 100) sadržava proizvode koji su vezani uz duhan, pri čemu su proizvodi koji su vezani uz duhan odabrani iz sljedećih skupina: cigarete, cigarilosi, cigare, štapići koji sadržavaju duhan, duhan bez dima, naprave koje simuliraju pušenje, naprave za inhaliranje bez izgaranja duhana, rezervoari s aromom.
Use according to Claim 19 for the treatment or prevention of chronic obstructive pulmonary disease. 
Uporaba prema patentnom zahtjevu 19 za liječenje ili prevenciju kronične opstruktivne bolesti pluća.
In view of the above, the compounds of formulae (I) and (Ia) are useful as vanilloid receptor blockers, e.g., in the treatment of diseases and conditions in which vanilloid receptor activation plays a role or is implicated. 
Imajući u vidu gore izneseno, spojevi formula (1) 1 (Ia) mogu se upotrijebiti kao blokeri vaniloid receptora, npr. u liječenju bolesti i stanja u kojima neku ulogu ima aktivacija vaniloid receptora ili je ona u njih uključena.
at between about 6.8 to about 7.0, or 
na oko 6,8 do oko 7,0, ili
The vector according to claim 6, which is selected from the group consisting of a plasmid, a viral vector, non-episomal mammalian vector, expression vector and a recombinant expression vector. 
Vektor u skladu s patentnim zahtjevom 6, naznačen time što se bira iz skupine koju čine plazmid, virusni vektor, neepisomski sisavački vektor, ekspresijski vektor i rekombinantni ekspresijski vektor.
The method of claim 1, wherein the aluminum oxyhydroxide is administered at least once monthly for at least six months to the AD patient. The method of claim 1, wherein the aluminum oxyhydroxide is administered to the AD patient subcutaneously in the upper arm. 
Aluminijev oksihidroksid za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se kod aluminijeve soli radi o aluminijevom oksihidroksidu, koja se primjenjuje na AD-pacijentu najmanje jednom mjesečno u vremenskom periodu od najmanje šest mjeseci.
preparing a compound of formula 27 via halogenation of the prepared compound of formula 28 followed by hydroxylation; 
pripravu spoja s formulom 27 putem halogeniranja pripremljenog spoja s formulom 28 nakon čega slijedi hidroksilacija;
The combination dosage form of claim 5 wherein the subcoat layer comprises polyvinyl alcohol and polyethylene glycol. 
Kombinirani oblik doziranja u skladu s patentnim zahtjevom 7, naznačen time, da donji sloj premaza sadržava polivinil alkohol i polietilen glikol.